Equities

Orthocell Ltd

Orthocell Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.365
  • Today's Change-0.01 / -2.67%
  • Shares traded133.95k
  • 1 Year change0.00%
  • Beta1.0813
Data delayed at least 20 minutes, as of May 31 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes CelGro, Striate+, Remplir, and SmrtGraft. CelGro is a collagen medical device that facilitates tissue reconstruction and healing in a variety of dental and orthopedic reconstructive applications. CelGro is manufactured using a SMRT manufacturing process to preserve the natural collagen structure. Striate+ is used for dental GBR applications. Remplir is for peripheral nerve reconstruction. SmrtGraft is for tendon repair. Its other major products are autologous cell therapy, which focuses on regenerating damaged tendon and cartilage tissue. It is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.

  • Revenue in AUD (TTM)6.06m
  • Net income in AUD-7.42m
  • Incorporated2006
  • Employees--
  • Location
    Orthocell LtdBuilding 191 Murdoch UniversitySouth Street MurdochPERTH 6150AustraliaAUS
  • Phone+61 89360-2888
  • Fax+61 89360-2899
  • Websitehttp://www.orthocell.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BCAL Diagnostics Ltd3.67m-5.00m44.15m----7.26--12.02-0.0227-0.02270.01660.02410.4493--3.21---61.10-54.01-67.83-62.57-----136.00-248.64---131.830.1985--298.6363.18-49.51--91.62--
Vitura Health Ltd119.67m9.40m46.65m121.004.921.1912.340.38980.01650.01650.20990.06811.9811.2210.51989,034.2015.2515.2922.3021.0631.23--7.706.921.185,598.190.2359--75.16--128.31146.9554.86--
Starpharma Holdings Ltd10.63m-8.40m47.38m50.00--1.37--4.46-0.0205-0.02050.02590.08370.20920.2822.10---16.53-28.47-20.70-33.6692.6771.62-79.00-391.825.22--0.0833---14.10-3.223.19--11.58--
Biotron Ltd1.65m-4.02m48.72m4.00--26.06--29.62-0.0045-0.00450.00180.00210.3587-------87.73-64.30-103.46-74.43-156.30-108.03-244.54-231.62----0.0148---8.16-2.48-25.59------
Anteotech Ltd526.75k-11.46m59.14m40.00--11.10--112.28-0.0056-0.00560.00030.00220.0552--2.62---120.11-68.55-145.22-75.44-----2,176.15-1,432.10----0.1729---46.6511.41-18.08--25.84--
Cynata Therapeutics Ltd436.25k-13.65m60.18m0.00--4.90--137.94-0.0873-0.08730.00270.06830.0257--4.26---80.33-38.07-87.15-41.10-----3,127.93-513.73----0.00---94.9619.81-162.20------
Biome Australia Ltd10.24m-2.86m71.30m30.00--33.07--6.96-0.0141-0.01410.05060.01011.371.936.04341,434.70-38.27---74.60--61.29---27.97--0.9514-15.920.4032--73.58--32.20------
Neurotech International Ltd1.28m-4.98m72.23m----13.21--56.55-0.0058-0.00580.00150.00540.1826-0.11495.67---71.23-197.33-74.66-255.24100.0779.57-390.03-1,043.8818.35--0.00--106.2283.24-131.75------
Percheron Therapeutics Ltd624.51k-10.85m73.03m8.00--4.44--116.93-0.0157-0.01570.00090.01820.0328--0.3224---56.94-72.09-66.58-81.73-----1,737.37-6,558.90----0.001--1,026.1672.03-95.81------
Next Science Ltd33.44m-24.53m75.84m----3.92--2.27-0.106-0.1060.14290.06631.467.478.33---107.19-74.40-136.06-90.3173.2076.98-73.36-128.263.45-50.370.0698--89.3650.80-28.29---2.28--
Orthocell Ltd6.06m-7.42m76.40m----33.39--12.62-0.0369-0.03690.03010.01090.21821.5027.68---26.73-32.67-31.96-38.5377.1163.04-122.55-374.464.36--0.2586--215.2451.5331.39--11.07--
Actinogen Medical Ltd337.51k-14.87m77.78m----5.66--230.45-0.0073-0.00730.00020.00510.0211--0.7341---92.99-45.55-105.88-48.24-----4,405.86-5,369.76---294.930.0037--792.7431.88-13.21--166.95--
PharmAust Limited1.85m-7.79m83.14m52.00--10.53--44.92-0.0236-0.02010.00550.020.1977--6.71---83.26-25.56-96.46-28.7820.0690.73-421.04-59.16---104.650.00---13.533.42-263.63---47.47--
Paradigm Biopharmaceuticals Ltd8.67m-69.00m87.45m----2.60--10.09-0.2296-0.22960.02880.09620.1298--2.25---103.34-40.96-127.58-44.1399.87---796.30-466.85---348.760.0085--7.5825.42-32.26------
Argenica Therapeutics Ltd92.21k-4.67m94.57m----11.58--1,025.59-0.0511-0.05110.0010.06650.0109--0.6384---55.31---69.00-------5,067.62-----6,663.200.00--2,340.00---17.71------
Data as of May 31 2024. Currency figures normalised to Orthocell Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

2.35%Per cent of shares held by top holders
HolderShares% Held
Sandhurst Trustees Ltd.as of 23 Aug 20234.91m2.35%
Data from 29 Feb 2024 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.